The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can mean a heightened ...

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

In the wake of the elimination diets, 38% of the parents reported no improvement in their child’s AD, 35% reported a 25% ...

The Phase III ECZTEND study reported that patients treated with Adbry demonstrated long term safety and efficacy for up to ...

Occupational contact dermatitis was common among construction workers, with metals, epoxy resin, and rubber identified as common etiological sources.

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

The substantial correlation between prurigo nodularis (PN) and atopic dermatitis (AD) has been highlighted by a recent ...

Individuals who suffer from atopic dermatitis are three times more likely to develop anxiety, depression and sleep ...

A live and archived webcast of the fireside chats and presentations will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.